Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Impact of Oxidative Metabolism on the Cytotoxic and Genotoxic Potential of Genistein in Human Colon Cancer Cells.

Schroeter A, Aichinger G, Stornig K, Marko D.

Mol Nutr Food Res. 2019 Jan;63(2):e1800635. doi: 10.1002/mnfr.201800635. Epub 2018 Dec 10.

PMID:
30536621
2.

First insights into Alternaria multi-toxin in vivo metabolism.

Puntscher H, Hankele S, Tillmann K, Attakpah E, Braun D, Kütt ML, Del Favero G, Aichinger G, Pahlke G, Höger H, Marko D, Warth B.

Toxicol Lett. 2019 Feb;301:168-178. doi: 10.1016/j.toxlet.2018.10.006. Epub 2018 Oct 12.

PMID:
30321595
3.

The Hop Polyphenols Xanthohumol and 8-Prenyl-Naringenin Antagonize the Estrogenic Effects of Fusarium Mycotoxins in Human Endometrial Cancer Cells.

Aichinger G, Beisl J, Marko D.

Front Nutr. 2018 Sep 19;5:85. doi: 10.3389/fnut.2018.00085. eCollection 2018.

4.

Hybrid in silico/in vitro target fishing to assign function to "orphan" compounds of food origin - The case of the fungal metabolite atromentin.

Dellafiora L, Aichinger G, Geib E, Sánchez-Barrionuevo L, Brock M, Cánovas D, Dall'Asta C, Marko D.

Food Chem. 2019 Jan 1;270:61-69. doi: 10.1016/j.foodchem.2018.07.027. Epub 2018 Jul 4.

PMID:
30174092
5.

Delphinidin protects colon carcinoma cells against the genotoxic effects of the mycotoxin altertoxin II.

Aichinger G, Puntscher H, Beisl J, Kütt ML, Warth B, Marko D.

Toxicol Lett. 2018 Mar 1;284:136-142. doi: 10.1016/j.toxlet.2017.12.002. Epub 2017 Dec 5.

PMID:
29217480
6.

In vitro combinatory effects of the Alternaria mycotoxins alternariol and altertoxin II and potentially involved miRNAs.

Vejdovszky K, Sack M, Jarolim K, Aichinger G, Somoza MM, Marko D.

Toxicol Lett. 2017 Feb 5;267:45-52. doi: 10.1016/j.toxlet.2016.12.011. Epub 2016 Dec 19.

7.

Genistein and delphinidin antagonize the genotoxic effects of the mycotoxin alternariol in human colon carcinoma cells.

Aichinger G, Beisl J, Marko D.

Mol Nutr Food Res. 2017 Feb;61(2). doi: 10.1002/mnfr.201600462. Epub 2016 Oct 14.

PMID:
27628123
8.

11-Substituted Benzo[c]phenanthridines: New Structures and Insight into Their Mode of Antiproliferative Action.

Clement B, Girreser U, Steinhauer TN, Meier C, Marko D, Aichinger G, Kaltefleiter I, Stenzel L, Heber D, Weide M, Wolschendorf U, Zebothsen I, Zur Nieden D.

ChemMedChem. 2016 Oct 6;11(19):2155-2170. doi: 10.1002/cmdc.201600199. Epub 2016 Aug 22.

PMID:
27546098
9.

Bilberry extract, its major polyphenolic compounds, and the soy isoflavone genistein antagonize the cytostatic drug erlotinib in human epithelial cells.

Aichinger G, Pahlke G, Nagel LJ, Berger W, Marko D.

Food Funct. 2016 Aug 10;7(8):3628-36. doi: 10.1039/c6fo00570e. Epub 2016 Aug 3.

PMID:
27485636
10.

Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients.

Fritz R, Hetzelt N, Ilk R, Hohenadl C, van der Velden MV, Aichinger G, Portsmouth D, Kistner O, Howard MK, Barrett PN, Kreil TR.

Open Forum Infect Dis. 2014 Aug 25;1(2):ofu072. doi: 10.1093/ofid/ofu072. eCollection 2014 Sep.

11.

An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial.

Wressnigg N, van der Velden MV, Portsmouth D, Draxler W, O'Rourke M, Richmond P, Hall S, McBride WJ, Redfern A, Aaskov J, Barrett PN, Aichinger G.

Clin Vaccine Immunol. 2015 Mar;22(3):267-73. doi: 10.1128/CVI.00546-14. Epub 2014 Dec 24.

12.

Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.

Aichinger G, Grohmann-Izay B, van der Velden MV, Fritsch S, Koska M, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN.

Clin Vaccine Immunol. 2015 Jan;22(1):46-55. doi: 10.1128/CVI.00275-14. Epub 2014 Oct 29.

13.

A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.

Wressnigg N, Barrett PN, Pöllabauer EM, O'Rourke M, Portsmouth D, Schwendinger MG, Crowe BA, Livey I, Dvorak T, Schmitt B, Zeitlinger M, Kollaritsch H, Esen M, Kremsner PG, Jelinek T, Aschoff R, Weisser R, Naudts IF, Aichinger G.

Clin Vaccine Immunol. 2014 Nov;21(11):1490-9. doi: 10.1128/CVI.00406-14. Epub 2014 Sep 3.

14.

Superior in vitro stimulation of human CD8+ T-cells by whole virus versus split virus influenza vaccines.

Halbroth BR, Heil A, Distler E, Dass M, Wagner EM, Plachter B, Probst HC, Strand D, Hartwig UF, Karner A, Aichinger G, Kistner O, Landfester K, Herr W.

PLoS One. 2014 Jul 29;9(7):e103392. doi: 10.1371/journal.pone.0103392. eCollection 2014.

15.

Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.

van der Velden MV, Geisberger A, Dvorak T, Portsmouth D, Fritz R, Crowe BA, Herr W, Distler E, Wagner EM, Zeitlinger M, Sauermann R, Stephan C, Ehrlich HJ, Barrett PN, Aichinger G.

Clin Vaccine Immunol. 2014 Jun;21(6):867-76. doi: 10.1128/CVI.00065-14. Epub 2014 Apr 16.

16.

Oxidative metabolism enhances the cytotoxic and genotoxic properties of the soy isoflavone daidzein.

Baechler SA, Schroeter A, Walker J, Aichinger G, Marko D.

Mol Nutr Food Res. 2014 Jun;58(6):1269-81. doi: 10.1002/mnfr.201300531. Epub 2014 Mar 3.

PMID:
24585454
17.

Lyme disease vaccination: safety first - authors' reply.

Barrett PN, Crowe BA, Wressnigg N, Portsmouth D, Aichinger G.

Lancet Infect Dis. 2014 Jan;14(1):12-13. doi: 10.1016/S1473-3099(13)70362-1. No abstract available.

PMID:
24355029
18.

Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.

van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, Richmond P, Lee BW, Kistner O, Ehrlich HJ, Barrett PN, Aichinger G.

J Infect Dis. 2014 Jan 1;209(1):12-23. doi: 10.1093/infdis/jit498. Epub 2013 Sep 16.

PMID:
24041789
19.

Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.

Wressnigg N, Pöllabauer EM, Aichinger G, Portsmouth D, Löw-Baselli A, Fritsch S, Livey I, Crowe BA, Schwendinger M, Brühl P, Pilz A, Dvorak T, Singer J, Firth C, Luft B, Schmitt B, Zeitlinger M, Müller M, Kollaritsch H, Paulke-Korinek M, Esen M, Kremsner PG, Ehrlich HJ, Barrett PN.

Lancet Infect Dis. 2013 Aug;13(8):680-9. doi: 10.1016/S1473-3099(13)70110-5. Epub 2013 May 10.

PMID:
23665341
20.

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.

van der Velden MV, Aichinger G, Pöllabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, Zeitlinger M, Kollaritsch H, Vesikari T, Ehrlich HJ, Barrett PN.

Vaccine. 2012 Sep 21;30(43):6127-35. doi: 10.1016/j.vaccine.2012.07.077. Epub 2012 Aug 8.

PMID:
22884662
21.

[Lung ultrasound in acute and critical care medicine].

Zechner PM, Seibel A, Aichinger G, Steigerwald M, Dorr K, Scheiermann P, Schellhaas S, Cuca C, Breitkreutz R; Arbeitsgruppe des Moduls 5 in Anästhesie Fokussierte Sonographie der DGAI.

Anaesthesist. 2012 Jul;61(7):608-17. doi: 10.1007/s00101-012-2046-9. Review. German.

PMID:
22772347
22.

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.

Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1.

PMID:
22475864
23.

A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals.

Ehrlich HJ, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Portsmouth D, Kistner O, Barrett PN.

Clin Infect Dis. 2012 Apr;54(7):946-54. doi: 10.1093/cid/cir959. Epub 2012 Jan 19.

24.

Cardiac movement identified on prehospital echocardiography predicts outcome in cardiac arrest patients.

Aichinger G, Zechner PM, Prause G, Sacherer F, Wildner G, Anderson CL, Pocivalnik M, Wiesspeiner U, Fox JC.

Prehosp Emerg Care. 2012 Apr-Jun;16(2):251-5. doi: 10.3109/10903127.2011.640414. Epub 2012 Jan 11.

PMID:
22235765
25.

Clinical development of a Vero cell culture-derived seasonal influenza vaccine.

Ehrlich HJ, Berezuk G, Fritsch S, Aichinger G, Singer J, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN.

Vaccine. 2012 Jun 19;30(29):4377-86. doi: 10.1016/j.vaccine.2011.11.114. Epub 2011 Dec 13.

PMID:
22172502
26.

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.

Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, Ehrlich HJ.

Vaccine. 2012 Jan 5;30(2):329-35. doi: 10.1016/j.vaccine.2011.10.088. Epub 2011 Nov 12.

PMID:
22080174
27.

Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial.

Aichinger G, Ehrlich HJ, Aaskov JG, Fritsch S, Thomasser C, Draxler W, Wolzt M, Müller M, Pinl F, Van Damme P, Hens A, Levy J, Portsmouth D, Holzer G, Kistner O, Kreil TR, Barrett PN.

Vaccine. 2011 Nov 21;29(50):9376-84. doi: 10.1016/j.vaccine.2011.09.125. Epub 2011 Oct 12.

PMID:
22001875
28.

Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection.

Holzer GW, Coulibaly S, Aichinger G, Savidis-Dacho H, Mayrhofer J, Brunner S, Schmid K, Kistner O, Aaskov JG, Falkner FG, Ehrlich H, Barrett PN, Kreil TR.

Vaccine. 2011 May 31;29(24):4132-41. doi: 10.1016/j.vaccine.2011.03.089. Epub 2011 Apr 6.

PMID:
21477673
29.

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial.

Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O, Ehrlich HJ.

Lancet. 2011 Feb 26;377(9767):751-9. doi: 10.1016/S0140-6736(10)62228-3. Epub 2011 Feb 15.

PMID:
21329971
30.

Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.

Crowe BA, Brühl P, Gerencer M, Schwendinger MG, Pilz A, Kistner O, Koelling-Schlebusch K, Aichinger G, Singer J, Zeitlinger M, Müller M, Ehrlich H, Barrett PN.

Vaccine. 2010 Dec 16;29(2):166-73. doi: 10.1016/j.vaccine.2010.10.065. Epub 2010 Nov 4.

PMID:
21055500
31.

Immunodominant T-cell epitopes of hnRNP-A2 associated with disease activity in patients with rheumatoid arthritis.

Trembleau S, Hoffmann M, Meyer B, Nell V, Radner H, Zauner W, Hammer J, Aichinger G, Fischer G, Smolen J, Steiner G.

Eur J Immunol. 2010 Jun;40(6):1795-808. doi: 10.1002/eji.200939482.

32.

Prehospital lung ultrasound in the distinction between pulmonary edema and exacerbation of chronic obstructive pulmonary disease.

Zechner PM, Aichinger G, Rigaud M, Wildner G, Prause G.

Am J Emerg Med. 2010 Mar;28(3):389.e1-2. doi: 10.1016/j.ajem.2009.07.021. Epub 2010 Jan 28.

PMID:
20223411
33.

Analysis of the human cytomegalovirus pp65-directed T-cell response in healthy HLA-A2-positive individuals.

Schalich J, Vytvytska O, Zauner W, Fischer MB, Buschle M, Aichinger G, Klade CS.

Biol Chem. 2008 May;389(5):551-9.

PMID:
18953722
34.

Detailed analysis of the effects of Glu/Lys beta69 human leukocyte antigen-DP polymorphism on peptide-binding specificity.

Berretta F, Butler RH, Diaz G, Sanarico N, Arroyo J, Fraziano M, Aichinger G, Wucherpfennig KW, Colizzi V, Saltini C, Amicosante M.

Tissue Antigens. 2003 Dec;62(6):459-71.

PMID:
14617029
35.

Role of donor and recipient antigen-presenting cells in priming and maintaining T cells with indirect allospecificity.

Frasca L, Amendola A, Hornick P, Brookes P, Aichinger G, Marelli-Berg F, Lechler RI, Lombardi G.

Transplantation. 1998 Nov 15;66(9):1238-43.

PMID:
9825823
36.

Expression of recombinant anti-E-selectin single-chain Fv antibody fragments in stably transfected insect cell lines.

Mahiouz DL, Aichinger G, Haskard DO, George AJ.

J Immunol Methods. 1998 Mar 15;212(2):149-60.

PMID:
9672203
37.

Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins.

Aichinger G, Karlsson L, Jackson MR, Vestberg M, Vaughan JH, Teyton L, Lechler RI, Peterson PA.

J Biol Chem. 1997 Nov 14;272(46):29127-36.

38.

In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM.

Lightstone L, Hargreaves R, Bobek G, Peterson M, Aichinger G, Lombardi G, Lechler R.

Proc Natl Acad Sci U S A. 1997 May 27;94(11):5772-7.

39.

The endogenous pathway of MHC class II antigen presentation.

Lechler R, Aichinger G, Lightstone L.

Immunol Rev. 1996 Jun;151:51-79. Review. No abstract available.

PMID:
8872485
40.

CD4 monoclonal antibody VIT4 in human alloimmune response in vitro and in vivo.

Nachbaur D, Niederwieser D, Aichinger G, Aulitzky W, Tilg H, Eibl B, König P, Gattringer C, Majdic O, Stockinger H, Margreiter R, Oberhuber G, Födinger AM, Schwaighofer H, Huber C.

Immunobiology. 1996 Jan;195(1):33-46.

PMID:
8852599
41.

Endogenous pathway of class II presentation.

Aichinger G, Lechler RI.

Biochem Soc Trans. 1995 Aug;23(3):657-60. Review.

PMID:
8566437
42.

Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses.

Raz E, Carson DA, Parker SE, Parr TB, Abai AM, Aichinger G, Gromkowski SH, Singh M, Lew D, Yankauckas MA, et al.

Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9519-23.

43.

Structural analysis of anti-DR1 allorecognition by using DR1/H-2Ek hybrid molecules. Influence of the beta 2-domain correlates with CD4 dependence.

Lombardi G, Barber L, Aichinger G, Heaton T, Sidhu S, Batchelor JR, Lechler RI.

J Immunol. 1991 Sep 15;147(6):2034-40.

PMID:
1716292
44.

Structural relationship between HLA-A2-restricted and anti-A2 allospecific T-cell recognition: analysis by mutation of the codons for polymorphic and conserved residues.

Lombardi G, Matsui M, Moots R, Aichinger G, Sidhu S, Batchelor R, McMichael AJ, Frelinger J, Lechler R.

Transplant Proc. 1991 Feb;23(1 Pt 1):446-8. No abstract available.

PMID:
1703692
45.

Limited regions of the alpha 2-domain alpha-helix control anti-A2 allorecognition: an analysis using a panel of A2 mutants.

Lombardi G, Matsui M, Moots R, Aichinger G, Sidhu S, Batchelor R, Frelinger J, Lechler R.

Immunogenetics. 1991;34(3):149-56.

PMID:
1894309
46.

Further evidence for lymphokine overproduction in severe aplastic anemia.

Hinterberger W, Adolf G, Aichinger G, Dudczak R, Geissler K, Höcker P, Huber C, Kalhs P, Knapp W, Köller U, et al.

Blood. 1988 Jul;72(1):266-72.

47.
48.

Nonthyroid autoantibodies in obese strain (OS) chickens.

Aichinger G, Kofler H, Diaz-Merida O, Wick G.

Clin Immunol Immunopathol. 1984 Jul;32(1):57-69.

PMID:
6428787
49.

Studies on the cytochrome P-450 product complexes formed during the metabolism of N,N-dimethylaniline.

Hlavica P, Aichinger G.

Biochim Biophys Acta. 1978 Nov 15;544(1):185-99.

PMID:
718995
50.

[Basic tricyclic oxyiminoethers and their pharmacological properties].

Aichinger G, Behner O, Hoffmeister F, Schütz S.

Arzneimittelforschung. 1969 Jun;19:Suppl 5a:838+. German. No abstract available.

PMID:
5819763

Supplemental Content

Loading ...
Support Center